Article Information
History
- September 30, 2021.
Article Versions
- Version 1 (September 27, 2021 - 11:43).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Chiara Ronchinia,*,
- Sara Gandinib,
- Sebastiano Pasqualatob,
- Luca Mazzarellab,
- Federica Facciottib,
- Marina Mapellib,
- IEO Covid Teamb,c,
- Gianmaria Frige’a,
- Rita Passerinic,
- Luca Pased,
- Silvio Capizzie,
- Fabrizio Mastrillie,
- Roberto Orecchiaf,
- Gioacchino Natolib and
- Pier Giuseppe Peliccib
- aClinical Genomics, European Institute of Oncology IRCCS, Milan, Italy
- bDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Milano, Italy
- cDivision of Laboratory Medicine, European Institute of Oncology IRCCS, Milan, Italy
- dOccupational Medicine, European Institute of Oncology IRCCS, Milan, Italy
- eMedical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy
- fScientific Directorate, European Institute of Oncology IRCCS, Milan, Italy
- ↵*Correspondence to:
Chiara Ronchini or Pier Giuseppe Pelicci, chiara.ronchini{at}ieo.it, piergiuseppe.pelicci{at}ieo.it, Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy
Posted September 30, 2021.
Lower probability and shorter duration of infections after Covid-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs
